Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

Conclusions. Two doses of AS03-adjuvanted H7N9 vaccine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy adults.
Clinical Trials Registration. NCT01999842.

Source: The Journal of Infectious Diseases - November 13, 2016 Category: Infectious Diseases Authors: Madan, A., Segall, N., Ferguson, M., Frenette, L., Kroll, R., Friel, D., Soni, J., Li, P., Innis, B. L., Schuind, A. Tags: VIRUSES Source Type: research